01Jul
Novartis and Alcon FCPA Enforcement Action: Lessons Learned (Part III of III)
At the outset, Novartis is “lucky” – the settlement is relatively positive, despite its 2016 SEC enforcement action in China. Given Novartis weak culture of compliance (if anything, a better description may be a culture of non-compliance) and its status as a recidivist, Novartis could have been slammed with a stiffer enforcement action, including assignment of an independent corporate compliance monitor and a higher penalty. ...
By:
Michael Volkov
Related
2020 is drawing to a close, but the heat of the SPAC, which will be hot starting in 2019, has not di...
Read More >
OSHA just finalized the proposed rule on occupational exposure to beryllium and beryllium compounds ...
Read More >
Despite the global impact of the COVID-19 pandemic, Qatar has been able to maintain its extended per...
Read More >
In most jurisdictions, it is standard practice to include a “no-rehire” clause when negotiating a ...
Read More >
The New Jersey Department of Labor and Workforce Development (NJDLWD) has announced it has issued tw...
Read More >
The EEOC has released its annual report on the number of discrimination charges filed across the cou...
Read More >